180 related articles for article (PubMed ID: 37321669)
21. Long-term outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: Single centre experience from a large tertiary care teaching hospital in Southern India.
Goel R; Danda D; Joseph G; Ravindran R; Kumar S; Jayaseelan V; Jayaseelan L; Bacon P
Semin Arthritis Rheum; 2018 Apr; 47(5):718-726. PubMed ID: 29096935
[TBL] [Abstract][Full Text] [Related]
22. TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study.
Gudbrandsson B; Molberg Ø; Palm Ø
Arthritis Res Ther; 2017 May; 19(1):99. PubMed ID: 28521841
[TBL] [Abstract][Full Text] [Related]
23. Childhood-onset versus adult-onset Takayasu arteritis: A study of 141 patients from Turkey.
Karabacak M; Kaymaz-Tahra S; Şahin S; Yıldız M; Adroviç A; Barut K; Direskeneli H; Kasapçopur Ö; Alibaz-Öner F
Semin Arthritis Rheum; 2021 Feb; 51(1):192-197. PubMed ID: 33383295
[TBL] [Abstract][Full Text] [Related]
24. Biological treatments in giant cell arteritis & Takayasu arteritis.
Samson M; Espígol-Frigolé G; Terrades-García N; Prieto-González S; Corbera-Bellalta M; Alba-Rovira R; Hernández-Rodríguez J; Audia S; Bonnotte B; Cid MC
Eur J Intern Med; 2018 Apr; 50():12-19. PubMed ID: 29146018
[TBL] [Abstract][Full Text] [Related]
25. Management of Takayasu arteritis.
Misra DP; Singh K; Rathore U; Kavadichanda CG; Ora M; Jain N; Agarwal V
Best Pract Res Clin Rheumatol; 2023 Mar; 37(1):101826. PubMed ID: 37246052
[TBL] [Abstract][Full Text] [Related]
26. Rapid control of disease activity by tocilizumab in 10 'difficult-to-treat' cases of Takayasu arteritis.
Goel R; Danda D; Kumar S; Joseph G
Int J Rheum Dis; 2013 Dec; 16(6):754-61. PubMed ID: 24382284
[TBL] [Abstract][Full Text] [Related]
27. Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre.
Zhou Z; Fang C; Wang L; Li J; Yang Y; Zhang L; Jin S; Zeng X; Tian X
RMD Open; 2024 Mar; 10(1):. PubMed ID: 38519108
[TBL] [Abstract][Full Text] [Related]
28. Comparing treatment options for large vessel vasculitis.
Macaluso F; Marvisi C; Castrignanò P; Pipitone N; Salvarani C
Expert Rev Clin Immunol; 2022 Aug; 18(8):793-805. PubMed ID: 35714219
[TBL] [Abstract][Full Text] [Related]
29. Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis.
Barra L; Yang G; Pagnoux C;
Autoimmun Rev; 2018 Jul; 17(7):683-693. PubMed ID: 29729444
[TBL] [Abstract][Full Text] [Related]
30. Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study.
Kong X; Sun Y; Dai X; Wang L; Ji Z; Chen H; Jin X; Ma L; Jiang L
Ann Rheum Dis; 2022 Jan; 81(1):117-123. PubMed ID: 34362744
[TBL] [Abstract][Full Text] [Related]
31. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study).
Burmester GR; Rubbert-Roth A; Cantagrel A; Hall S; Leszczynski P; Feldman D; Rangaraj MJ; Roane G; Ludivico C; Lu P; Rowell L; Bao M; Mysler EF
Ann Rheum Dis; 2014 Jan; 73(1):69-74. PubMed ID: 23904473
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of tocilizumab for intractable Takayasu arteritis and
Isobe M; Maejima Y; Saji M; Tateishi U
J Cardiol; 2021 May; 77(5):539-544. PubMed ID: 33451862
[TBL] [Abstract][Full Text] [Related]
33. A retrospective cohort study to assess PET-CT findings and clinical outcomes in Takayasu arteritis: does 18F-fluorodeoxyglucose uptake in arteries predict relapses?
Janes ALF; Castro MF; Arraes AED; Savioli B; Sato EI; de Souza AWS
Rheumatol Int; 2020 Jul; 40(7):1123-1131. PubMed ID: 32200427
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of biological agents in the treatment of patients with Takayasu arteritis: a systematic review and meta-analysis.
Shuai ZQ; Zhang CX; Shuai ZW; Ge SL
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):250-262. PubMed ID: 33506914
[TBL] [Abstract][Full Text] [Related]
35. Statins reduce relapse rate in Takayasu arteritis.
Kwon OC; Oh JS; Park MC; Hong S; Lee CK; Yoo B; Kim YG
Int J Cardiol; 2019 Jul; 287():111-115. PubMed ID: 30824260
[TBL] [Abstract][Full Text] [Related]
36. Current Diagnosis and Management of Takayasu Arteritis.
As C; Danda D
Int Heart J; 2023; 64(4):519-534. PubMed ID: 37518335
[TBL] [Abstract][Full Text] [Related]
37. Tocilizumab treatment in childhood Takayasu arteritis: Case series of four patients and systematic review of the literature.
Batu ED; Sönmez HE; Hazırolan T; Özaltın F; Bilginer Y; Özen S
Semin Arthritis Rheum; 2017 Feb; 46(4):529-535. PubMed ID: 27515155
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in Takayasu arteritis.
Terao C; Yoshifuji H; Mimori T
Int J Rheum Dis; 2014 Mar; 17(3):238-47. PubMed ID: 24548718
[TBL] [Abstract][Full Text] [Related]
39. Childhood Takayasu arteritis: disease course and response to therapy.
Aeschlimann FA; Eng SWM; Sheikh S; Laxer RM; Hebert D; Noone D; Twilt M; Pagnoux C; Benseler SM; Yeung RSM
Arthritis Res Ther; 2017 Nov; 19(1):255. PubMed ID: 29166923
[TBL] [Abstract][Full Text] [Related]
40. Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center.
Tombetti E; Franchini S; Papa M; Sabbadini MG; Baldissera E
J Rheumatol; 2013 Dec; 40(12):2047-51. PubMed ID: 24187104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
